Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company developing drug candidates targeting the tyrosine kinase 2 (TYK2) inhibitor which plays a crucial role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company's pipeline of next-generation TYK2 inhibitors features a promising brain-penetrant candidate, potentially the first and best-in-class, for treating multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation. Additionally, it includes a potential first and best-in-class topical candidate for immune-mediated dermatologic diseases. As of June 2024, the company had 4 drug candidates in preclinical stages in its pipeline.